Table 2. Patients’ characteristics, cohort #1.
| # | primary site | stage | sex | Age | chemotherapy | HPV |
|---|---|---|---|---|---|---|
| #1 | oral cavity | T3N2cM0 | f | 49 | primary CRT CIS (20 mg/m2/d, 2 weeks) |
neg. |
| #2 | oral cavity | T3N0M0 | m | 50 | primary CRT CIS (40 mg/m2/w, 7 weeks) |
n/a |
| #3 | oral cavity | T4aN2cM0 | m | 61 | primary CRT CIS (40 mg/m2/w, 7 weeks) |
pos. |
| #4 | oral cavity | T1N2bM0 | m | 68 | primary CRT CIS (40 mg/m2/w, 7 weeks) CARBO (AUC-2, 3 weeks) |
pos. |
| #5 | nasopharynx | T3N2bM0 | m | 60 | primary CRT CIS (20 mg/m2/d, 2 weeks) |
n/a |
| #6 | larynx | T3N2cM0 | f | 45 | primary CRT CIS (40 mg/m2/w, 7 weeks) |
n/a |
| #7 | oral cavity | T2N2bM0 | m | 68 | primary CRT CARBO (AUC-6, 2 weeks) |
neg. |
| #8 | pharynx | T4aN3bM0 | m | 76 | primary CRT MIT-C (10 mg/m2/w, 2 weeks) |
n/a |
| #9 | oral cavity | T3N2bM0 | m | 52 | adjuvant CRT CIS (20 mg/m2/d, 2 weeks) |
neg. |
| #10 | oral cavity | T1N1M0 | m | 50 | adjuvant CRT CIS (20 mg/m2/d, 2 weeks) 5-FU (600 mg/m2/w, 2 weeks) |
neg. |
| #11 | pharynx | T1N2bM0 | m | 52 | adjuvant CRT CIS (20 mg/m2/d, 2 weeks) |
n/a |
| #12 | larynx | T3N2cM0 | m | 63 | adjuvant CRT CIS (20 mg/m2/d, 2 weeks) |
n/a |
| #13 | larynx | T4aN1M0 | m | 53 | adjuvant CRT CIS (20 mg/m2/d, 2 weeks) |
n/a |
| #14 | larynx | T1aN0M0 | m | 70 | adjuvant CRT CIS (30 mg/m2/w, 7 weeks) |
n/a |
| #15 | acoustic meatus | T4N1M0 | f | 64 | adjuvant CRT CARBO (AUC-6, 2 weeks) |
n/a |
| #16 | oral cavity | T1N2bM1 | f | 46 | palliative CT MTX (40 mg/m2/w, 6 weeks) |
pos. |
| #17 | pharynx | T4aN0M1 | m | 58 | palliative CT MTX (40 mg/m2/w, 6 weeks) |
neg. |
| #18 | pharynx | T4aN2bM1 | m | 74 | palliative CT MTX (40 mg/m2/w, 6 weeks) |
neg. |
CRT: chemoradiotherapy; CIS: cisplatin (30–40mg/m2 weekly for 7 weeks, or 20mg/m2 daily in week 1 and 5); CARBO: carboplatin (AUC-area under the curve); MIT-C: mitomycin-C; 5-FU: 5-fluoruracil; MTX: methotrexate. Patients with adjuvant CRT underwent surgery before. Primary treated patients were treatment naive. n/a: not available. #16 was previously treated with CIS/5-FU/cetuximab; #17 and #18 were previously treated with taxane/CIS/5-FU, gemcitabine, cetuximab, and pembrolizumab.